Neuroendocrine Tumor Patients Gain a Second Lutetium Dotatate Option as FDA Approves Curium's Bexlutry Radioligand Injection
The FDA approved Curium's Bexlutry, a second lutetium Lu 177 dotatate therapy for adults with SSTR-positive GEP-NETs. Here is what it means for access.
Medical Daily ·